Evidence map›Paper›PMID 42424092›Full record

ArticleInternational journal of cancer2026

New-Onset Type 2 Diabetes Mellitus and Cancer Risk: A Matched Cohort Study in China Kadoorie Biobank.

Mengying Wang, Owen Tipping, Bowen Liu, Derrick A Bennett, Baiyong Shen, Siyi Zou, Shulin Zhao, Richard M Martin, Matthew Sperrin, Andrew G Renehan

Abstract read
In one paragraph

Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mengying WangDivision of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.ORCID https://orcid.org/0000-0001-7591-522X
Owen TippingDivision of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Bowen LiuClinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Derrick A BennettClinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Baiyong ShenDepartment of General Surgery, Pancreatic Disease Centre, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0002-3994-248X
Siyi ZouDepartment of General Surgery, Pancreatic Disease Centre, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shulin ZhaoDepartment of General Surgery, Pancreatic Disease Centre, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Richard M MartinDepartment of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Matthew SperrinCentre for Health Informatics, Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Andrew G RenehanDivision of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.ORCID https://orcid.org/0000-0002-9115-4405

Funding

Cancer Research UK 25 C18281/A29019EPSRC AI Hub for Causality in Healthcare EP/Y028856/1Manchester Biomedical Research Centre NIHR203308NIHR BRC-1215-20011UKRI AI programme and the Engineering and Physical Sciences Research Council
6 · The paper itself

Abstract

The prevalence of type 2 diabetes mellitus (T2DM) is rising rapidly in China and is linked to increased cancer risk, but causality remains unclear due to biases. We examined the causal effect of T2DM on cancer risk using bias-minimizing methods. We conducted a matched cohort study within China Kadoorie Biobank (median follow-up 49 months in men and 53 months in women). To minimize bias, we included only new-onset T2DM, applied sequential longitudinal matching, used pre-diagnosis BMI, and accounted for detection time bias. Stratified Cox models estimated sex-specific time-split hazard ratios (tsHRs). Results were triangulated with two-sample Mendelian Randomization (MR) in East Asians. After 1:3 matching, 8657 men and 13,680 women with T2DM were matched to unexposed individuals. T2DM was associated with increased risk of total cancers in men (tsHR 1.57, 95% CI 1.38-1.78) and women (tsHR 1.29, 95% CI 1.14-1.46). Site-specifically, T2DM was associated with liver cancer (men: 68 cases, tsHR 2.12, 95% CI 1.42-3.15; women: 43 cases, tsHR 2.39, 95% CI 1.42-4.04) and pancreatic cancer (men: 36 cases, tsHR 2.57, 95% CI 1.35-4.92; women: 33 cases, tsHR 3.95, 95% CI 1.92-8.13). No significant associations were observed for colorectal, lung, stomach, or breast cancers. In multivariable MR, genetic liability to T2DM was associated with pancreatic cancer after adjusting for BMI (OR 1.07, 95% CI 1.01-1.14, p = 0.03). In this large Chinese population, we found evidence for causal associations between T2DM and pancreatic cancer only, whereas evidence for other cancers was weak or discordant.

Indexed as

Diabetes Mellitus, Type 2NeoplasmsAdultAgedBiological Specimen BanksChinaCohort StudiesFemaleHumansMaleMendelian Randomization AnalysisMiddle AgedPancreatic NeoplasmsRisk FactorscancerChina Kadoorie biobanklongitudinal matchingMendelian randomisationtype 2 diabetes

Identifiers

PMID42424092
PMCPMC13637062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.